Michael McGuire, PharmD, BCPP

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.

On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.

Prior authorizations, injection site shortages, and care transition failures are undermining LAI antipsychotic adherence in patients with schizophrenia, one pharmacist explains.

Pharmacists play a vital role in mental health care, enhancing treatment continuity and bridging gaps between mental and physical health for patients with serious mental illness.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

Michael McGuire, PharmD, highlights the importance of early intervention in hospital settings, leveraging manufacturer programs, and navigating complex dosing regimens.

LAIs offer a variety of benefits, from improved medication adherence and relapse prevention to enhanced quality of life for individuals with schizophrenia.

Research has demonstrated a reduction in hospitalization risk associated with the use of LAIs, but some barriers can prevent the wider adoption of this approach.